An Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics and Safety of JZP-110 in Subjects with Normal or Impaired Renal Function and with End-Stage Renal Disease Requiring Hemodialysis
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs JZP 110 (Primary)
- Indications Hypersomnia; Narcolepsy; Renal failure; Sleep apnoea syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Jazz Pharmaceuticals plc
- 09 Jun 2017 Results presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
- 09 Jun 2017 New trial record
- 24 May 2017 According to a Jazz Pharmaceuticals plc media release, data from the study will be presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.